GenEdit
GenEdit is dedicated to developing innovative therapies through targeted delivery of genetic medicines. Their mission is to revolutionize genetic medicine by overcoming delivery challenges with their platform, NanoGalaxy®, enabling effective treatment of various diseases and rewriting patient health.
Industries
biotechnology
genetics
pharmaceutical
therapeutics
Nr. of Employees
small (1-50)
GenEdit
South San Francisco, California, United States, North America
Products
Nanoparticle-based delivery platform for genetic medicines
A platform for targeted delivery of nucleic acid therapeutics and gene editing cargos to enable therapeutic applications of genetic medicines by improving in vivo delivery and targeting.
Nanoparticle-based delivery platform for genetic medicines
A platform for targeted delivery of nucleic acid therapeutics and gene editing cargos to enable therapeutic applications of genetic medicines by improving in vivo delivery and targeting.
Expertise Areas
- Targeted delivery of nucleic acid therapeutics
- CRISPR/Cas9-based gene editing
- Platform-based therapeutic development
- Translational and preclinical development of genetic medicines
Key Technologies
- CRISPR/Cas9 gene editing
- Nanoparticle-based delivery platforms
- In vivo nucleic acid delivery
- Targeted delivery systems for genetic medicines